Sanofi in M&A mode, but under ITC scrutiny over insulin pen, FDA scrutiny over Ketek

 OpticlickReuters recently reported that Sanofi-Aventis' CEO is in "buying mode," mentioning BMS as a possible target. There had been some buzz on CafePharma about that in the past. But the company is dealing with other issues this week: notably, an investigation by ITC as to whether its Opticlick pen-type insulin delivery system violates patents held by NovoNordisk. FDA wants the company to halt clinical trials of its pediatric antibiotic, Ketek, based on evidence that the drug causes serious liver damage. (Presumably, the "cleanroom-garb-donning" pay lawsuit also launched this week will be less of a challenge). -AMS